JP7588080B2 - 抗末梢リンパ節アドレッシン抗体およびその使用 - Google Patents

抗末梢リンパ節アドレッシン抗体およびその使用 Download PDF

Info

Publication number
JP7588080B2
JP7588080B2 JP2021547170A JP2021547170A JP7588080B2 JP 7588080 B2 JP7588080 B2 JP 7588080B2 JP 2021547170 A JP2021547170 A JP 2021547170A JP 2021547170 A JP2021547170 A JP 2021547170A JP 7588080 B2 JP7588080 B2 JP 7588080B2
Authority
JP
Japan
Prior art keywords
antibody
pnad
amino acid
seq
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520088A5 (cg-RX-API-DMAC10.html
JP2022520088A (ja
Inventor
アブディ，レザ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Brigham and Women's Hospital Inc
Original Assignee
The Brigham and Women's Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Brigham and Women's Hospital Inc filed Critical The Brigham and Women's Hospital Inc
Publication of JP2022520088A publication Critical patent/JP2022520088A/ja
Publication of JP2022520088A5 publication Critical patent/JP2022520088A5/ja
Application granted granted Critical
Publication of JP7588080B2 publication Critical patent/JP7588080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Nanotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021547170A 2019-02-13 2020-02-12 抗末梢リンパ節アドレッシン抗体およびその使用 Active JP7588080B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962804797P 2019-02-13 2019-02-13
US62/804,797 2019-02-13
PCT/US2020/017879 WO2020167912A1 (en) 2019-02-13 2020-02-12 Anti-peripheral lymph node addressin antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2022520088A JP2022520088A (ja) 2022-03-28
JP2022520088A5 JP2022520088A5 (cg-RX-API-DMAC10.html) 2023-02-21
JP7588080B2 true JP7588080B2 (ja) 2024-11-21

Family

ID=71945935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547170A Active JP7588080B2 (ja) 2019-02-13 2020-02-12 抗末梢リンパ節アドレッシン抗体およびその使用

Country Status (11)

Country Link
US (3) US11028176B2 (cg-RX-API-DMAC10.html)
EP (1) EP3924386A4 (cg-RX-API-DMAC10.html)
JP (1) JP7588080B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210126078A (cg-RX-API-DMAC10.html)
CN (1) CN113795513B (cg-RX-API-DMAC10.html)
AU (1) AU2020221821A1 (cg-RX-API-DMAC10.html)
CA (1) CA3130103A1 (cg-RX-API-DMAC10.html)
IL (1) IL285409A (cg-RX-API-DMAC10.html)
MX (1) MX2021009662A (cg-RX-API-DMAC10.html)
SG (1) SG11202108560RA (cg-RX-API-DMAC10.html)
WO (1) WO2020167912A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021009662A (es) 2019-02-13 2021-09-08 Brigham & Womens Hospital Inc Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.
CN119306830B (zh) * 2023-07-11 2025-06-20 东莞市朋志生物科技有限公司 抗皮质醇抗体、检测皮质醇的试剂和试剂盒
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5538724A (en) * 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
WO1989012624A2 (en) 1988-06-14 1989-12-28 Cetus Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
DE69127749T2 (de) 1990-03-20 1998-04-16 The Trustees Of Columbia University In The City Of New York, New York, N.Y. Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region
IL98744A0 (en) 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
RO120148B1 (ro) 1997-03-14 2005-09-30 Idec Pharmaceuticals Corporation Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
JP5064612B2 (ja) 1999-04-09 2012-10-31 エーエムエージー ファーマシューティカルズ，インコーポレイテッド 還元された炭水化物類及び炭水化物誘導体で被覆された熱的に安定なコロイド状酸化鉄
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
US7060121B2 (en) 2003-06-25 2006-06-13 Hsing Kuang Lin Method of producing gold nanoparticle
CA2473429A1 (en) 2003-07-09 2005-01-09 National Research Council Of Canada Process for producing gold nanoparticles
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
WO2006041613A2 (en) 2004-10-05 2006-04-20 Nanomega Medical Corporation Nanoparticles for targeting hepatoma cells
US7291598B2 (en) 2005-01-04 2007-11-06 Gp Medical, Inc. Nanoparticles for protein drug delivery
US20080166706A1 (en) 2005-03-30 2008-07-10 Jin Zhang Novel gold nanoparticle aggregates and their applications
WO2007033090A2 (en) * 2005-09-13 2007-03-22 The Research Foundation Of State University Of New York At Buffalo Method for diagnosis of chronic allograft rejection
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
CN101679021B (zh) 2007-03-02 2014-04-30 伊利诺伊大学评议会 药物颗粒送递
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US9096660B2 (en) * 2010-04-26 2015-08-04 Abraxis Bioscience, Llc SPARC binding antibodies and uses thereof
WO2015108783A1 (en) 2014-01-16 2015-07-23 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
EP3166627A1 (en) * 2014-07-11 2017-05-17 Genentech, Inc. Notch pathway inhibition
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
CA3059938A1 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
MX2021009662A (es) 2019-02-13 2021-09-08 Brigham & Womens Hospital Inc Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of biological chemistry，2010年，Vol.285，p.40864-40878

Also Published As

Publication number Publication date
SG11202108560RA (en) 2021-09-29
KR20210126078A (ko) 2021-10-19
MX2021009662A (es) 2021-09-08
AU2020221821A1 (en) 2021-08-26
EP3924386A4 (en) 2023-01-04
WO2020167912A1 (en) 2020-08-20
US20250197508A1 (en) 2025-06-19
CN113795513B (zh) 2025-02-18
AU2020221821A2 (en) 2021-09-09
IL285409A (en) 2021-09-30
US20200255532A1 (en) 2020-08-13
US12180286B2 (en) 2024-12-31
US11028176B2 (en) 2021-06-08
US20210284740A1 (en) 2021-09-16
EP3924386A1 (en) 2021-12-22
CA3130103A1 (en) 2020-08-20
CN113795513A (zh) 2021-12-14
JP2022520088A (ja) 2022-03-28

Similar Documents

Publication Publication Date Title
US11939377B2 (en) Affinity matured CD22-specific monoclonal antibody and uses thereof
JP2025063213A (ja) トランスサイレチン（ｔｔｒ）アミロイドーシスに対する抗体療法及びそのためのヒト由来抗体
JP7460819B2 (ja) ヒト抗セマフォリン４ｄ抗体
ES2699801T3 (es) Moléculas de unión anti-alfa sinucleína
US20250197508A1 (en) Anti-Peripheral Lymph Node Addressin Antibodies and Uses Thereof
JP2019047807A (ja) Ｐｄｇｆ受容体ベータ結合ポリペプチド
JP2018035137A (ja) 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
JP2017113017A (ja) 抗ｃｄ１００抗体およびこれを使用するための方法
AU2014361856A1 (en) Novel anti-DPEP3 antibodies and methods of use
US20170369592A1 (en) Novel anti-fibroblast activation protein (fap) antibodies and uses derived thereof
JP6640181B2 (ja) 二重特異性抗原結合ポリペプチド
JP2019525727A (ja) 新規の抗ｔｎｆｒｓｆ２１抗体及び使用方法
US11542322B2 (en) Nano-theranostics for Parkinson's disease
HK40035879A (en) Bi-specific antigen-binding polypeptides
HK1233656A1 (en) Bi-specific antigen-binding polypeptides
HK1233656B (en) Bi-specific antigen-binding polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240418

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241111

R150 Certificate of patent or registration of utility model

Ref document number: 7588080

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150